A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

Summary

The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.

Timeline

Start

2019-12-02

Primary completion

2021-05-03

Completion

2021-05-17

Outcome

Met primary endpoint

release “CLUE Study), Tigulixostat showed serum uric acid (sUA)-lowering effects across all dose levels, and achieved a treatment target of sUA<5mg/dL as the primary” innoventbio.com ↗

Drugs

Indications